Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest Revenue
Below are the top drugs-generic stocks on the NASDAQ in terms of revenue.
The trailing-twelve-month revenue at Mylan (NASDAQ: MYL) is $6.39 billion. Mylan's ROA for the same period is 5.89%.
The trailing-twelve-month revenue at Salix Pharmaceuticals Ltd (NASDAQ: SLXP) is $605.72 million. Salix Pharmaceuticals had $665.87 million in total cash for the latest quarter.
The trailing-twelve-month revenue at Hi Tech Pharmacal Co (NASDAQ: HITK) is $230.00 million. Hi Tech Pharmacal's ROE for the same period is 23.17%.
The trailing-twelve-month revenue at Akorn (NASDAQ: AKRX) is $163.19 million. Akorn's operating margin for the same period is 26.68%.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Drugs-Generic Industry Highest Revenue NASDAQTrading Ideas
